PTO/SB/08A (08-03)

			MAN 8		
Substitu	ute for form 1449A/PT	10	PATENT & TRADERARE		Complete if Known
				Application Number	10/086,294
INF	ORMATION	I DIS	CLOSURE	Filing Date	February 28, 2002
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Nielsen, Loretta
				Art Unit	1635 1632
	(use as many sh	eets as	necessary)	Examiner Name	Lacourciere, K. Hama, J
Sheet	11.	of		Attorney Docket Number	016930-003712US

			U.S. PATENT DO	CUMENTS+	
		Document Number			
Examiner Initials*	Cite No.	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
774	AA	US-6,054,467	04-25-2000	Gjerset	
					
					•
					· · · · · · · · · · · · · · · · · · ·
				.	
					· · · · · · · · · · · · · · · · · · ·
			!		

	FOREIGN PATENT DOCUMENTS							
Examiner	Cite	Foreign Patent Document				Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Country Code ³	Number ⁴	Kind Code [®] (# known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T⁰
					·			
					_			
		1						
					·			

				
Examiner		1	Date	
Signature	Ann 1	\wedge		1 1176/00
Signature			Considered	1 41 00103

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Documents at www.uspio.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Applicant by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

TO MAR TRADENTS

Substitute for form 1449B/PTO

2

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known					
Application Number	10/086,294				
Filing Date	February 28, 2002				
First Named Inventor	Nielsen, Loretta				
Art Unit	1635 1632				
Examiner Name	Lacourciere, K. Hama, J.				
Attomey Docket Number	016930-003712US				

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials * Cite		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
977 AB		Blagosklonny, et al., "In Vitro Evaluation of A p53-Expressing Adenovirus As An Anti-Cancer Drug," Int. J. Cancer 67:386-392 (1996)				
1	AC	Brinckerhoff, et al., Human Gene Therapy 6:1065-1124 (August 1995)				
	AD	Chang, et al., "Restoration of the G ₁ Checkpoint and the Apoptotic Pathway Mediated by Wild-type p53 Sensitizes Squamous Cell Carcinoma of the Head and Neck to Radiotherapy," Arch Otolaryngol Head Neck Surg., 123:507-512 (1997)				
	AE	Delia, et al., Nature Medicine 2(7):724-725 (July 1996)				
	AF	Fujiwara, et al., "Induction of chemosensitivity in human lung cancer cells in Vivo by adenovirus-mediated transfer of the wild-type p53 gene," Cancer Research 54:2287-2291 (1994)				
	AG	Frank, et al., "Combination E2F-1 and p53 Gene Transfer Does Not Enhance Growth Inhibition in Human Squamous Cell Carcinoma of the Head and Neck," Clin. Cancer Research 4:2265-2272 (1998)				
	АН	Gallardo, et al., "Adenovirus-based Transfer of Wild-Type p53 Gene Increases Ovarian Tumor Radiosensitivity," Cancer Research 56:4891-4893 (1996)				
	AI	Gjerset, et al., "Use of Wild-Type p53 to Achieve Complete Treatment Sensitization of Tumor Cells Expressing Endogenous Mutant p53," Molecular Carcinogenesis 14:275-285 (1995)				
	AJ	Gurnani, et al., "Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer," Cancer Chemother Pharmacol. 44:143-151 (1999)				
	AK	Hehir, et al., Journal of Virology 70(12)8459-8467 (December 1996)				
	AL	Kalechman, et al., Journal of Immunology 156(3)1101-1109 (1996)				
	AM	Nguyen, et al., "Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer," J. Thorac. Cardiavasc. Surg. 112:1372-1377 (1996)				
1	AN	Nielsen, et al. "Adenovirus-mediated p53 Gene Therapy and Paclitaxel Have Synergistic Efficacy in Models of Human Head and Neck, Ovarian, Prostate, and Breast Cancer," Clin. Cancer Research 4:835-846 (1998)				

<u></u>			
Examiner	ا الما الما الما الما الما الما الما ال	Date	11111100
Signature	10000 100	Considered	1 4126105
		1	_

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)

Substitute for form 1449B/PTO Complete if Known Application Number 10/086,294 INFORMATION DISCLOS Filing Date February 28, 2002 STATEMENT BY APPLICANT First Named Inventor Nielsen, Loretta Art Unit 1635 1632 (use as many sheets as necessary) Examiner Name Lacourciere; K. Hama Sheet 3 of Attomey Docket Number 016930-003712US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Initials * No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Ogawa, et al., "Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent," Int. J. Cancer 73:367-370 (1997)	
	AP	Parsels, et al., "Prevention of Fluorodeoxyuridine-Induced Cytotoxicity and DNA Damage in HT29 Colon Carcinoma Cells by Conditional Expression of Wild-Type p53 Phenotype," Molecular Pharmacology 52:600-605 (1997)	
	AQ	Pirollo, et al., "p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy," Oncogene, 14:1735-1746 (1997)	
	AR	Sandig, et al., "Adenovirally transferred p16 ^{fNK4/CDKN2} and p53 genes cooperate to induce apoptotic tumor cell death," Nature Med., 3:313-319 (1997)	
	AS	Spitz, et al., "In Vivo Adenovirus-Mediated p53 Tumor Suppressor Gene Therapy for Colorectal Cancer," Anticancer Research, 16:3415-3422 (1996)	
	AT	Spitz, et al., "Adenoviral-mediated Wild-Type p53 Gene Expression Sensitizes Colorectal Cancer Cells to Ionizing Radiation," Clin. Cancer Research 2:1665-1671 (1996)	
	AU	Son, et al. "Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer," Proc. Natl. Acad. Sci. USA, 91:12669-12672 (1994)	
J	AV	Tishler, et al., British Journal of Cancer 74(27):S82-S85 (1996)	

60142442 v1

Examiner Signature To au d	Date Considered 4/26/05
-------------------------------	-------------------------

PTO	ICB	LPRA	103.	n


			\C ?		FICOSBIGA (GS-GS)
Substitu	te for form 1449A/P1	ro /	ig)		Complete if Known
		بز الأحد .	CLOSURE	Application Number	10/086,294
INF	ORMATION	I DI	S CLOSURE 👸	Filing Date	February 28, 2002
STA	STATEMENT BY ARPLICANTS			First Named Inventor	Nielsen, Loretta
				Art Unit	1635 1632
	(use as many sh	eets a	s necessary)	Examiner Name	Lacourciere, K. Hama, J.
Sheet	1	of	2	Attorney Docket Number	016930-003712US

	U.S. PATENT DOCUMENTS+							
		Document Number	D. A.Francisco Data	Name of But and				
Examiner Initials*	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Cotumns, Lines, Where Relevant Passages or Relevant Figures Appear			
			 					
			 					
		<u> </u>			·			
			-	 				
		_						
		<u> </u>		1				

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document				Name of Patentee or	Pages, Columns, Lines,		
		Country Code ³	Number ⁴	Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶	
9H	1	wo	98/28948	A1	11-02-1995	Board of Regents, The University of Texas			

Examiner Signature	doen the	Date Considered	4126105

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. \(^2\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^3\) Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \(^6\) Applicant is to place a check mark here if English language Translation is attached. \(^6\)



2

Sheet

2

Complete if Known						
Application Number	10/086,294					
Filing Date	February 28, 2002					
First Named Inventor	Nielsen, Loretta					
Art Unit	-1635 163Z					
Examiner Name	Lacourciere, K. Hama, J.					
Attomey Docket Number	016930-003712US					

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
91+	2	Tishler et al., Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53, Cancer Res. 1995 Dec 15;55(24):6021-5.				
- <u>-</u>						
			ļ			
······································						

Examiner Signature To au la	Date Considered 4196105
-----------------------------	-------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO	Complete if Known		
INFORMATION DISCLOSURE	Application Number	10/086,294	
INFORMATION DISCLOSURE	Filing Date	February 28, 2004	
STATEMENT BY APPLICANT	First Named Inventor	Nielsen et al.	
	Art Unit	1835 1632	
(use as many sheets as necessary)	Examiner Name	Lacourciero, K. Hama, J	
Sheet 3 of Consulation	Attorney Docket Number	016930-003712US	

	U.S. PATENT DOCUMENTS+									
	Document Number									
Examiner Initials*	Cite No. ¹	Number Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear					

	·	FO	REIGN PA	TENT DOCUME	ENTS		
0:4-	Foreign Patent Document				Name of Betastes as	Pages, Columns, Lines,	
No.1	Country Code ³	Number ⁴ Kind	Code ⁶ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	
AA	WO	95/10514	A1	04-20-1995	Schering Corp.		
AB	WO	95/28948	A1	11-02-1995	Univ. Texas		
AC	WO	97/23478	A1 .	07-03-1997	Schering Corp.		
		NON PA	ATENT LIT	ERATURE DO	CUMENTS		
Cite No.1		agazine, joumal, se	rial, symposi	ım, catalog, etc.), o	late, page(s), volume-issu		T ²
AD	HARRIS et al., "Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies" J. Natl. Cancer Inst. (1996) 88(20):1442-1455.						
AE						nd SCH58500 (p53	
AF					dazole increase the levels of	of transcriptionally	
	-						
	AA AB AC Cite No.1 AD AE	Cite No.¹ AA WO AB WO AC WO Cite No.¹ Cite No.¹ AD HARRIS et al., strategies° J. A AE NIELSEN et al Adenovirus) in AE TISHLER et al	Cite No.¹ AA WO 95/10514 AB WO 95/28948 AC WO 97/23478 NON PA Cite No.¹ AD HARRIS et al., "Structure and function strategies" J. Natl. Cancer Inst. (198 AE NIELSEN et al., "Combination thera Adenovirus) in preclinical cancer model. AE TISHLER et al. "Microtubule-active of the country of the cancer and ca	Cite No.¹ Country Code³ Number⁴ Kind Code⁵ (# known) AA WO 95/10514 A1 AB WO 95/28948 A1 AC WO 97/23478 A1 NON PATENT LIT Cite No.¹ Include name of the author (in CAPITAL LET (book, magazine, journal, serial, symposit publisher, city at strategies* J. Natl. Cancer Inst. (1996) 88(20):144 AE NIELSEN et al., "Combination therapy with the Fall Adenovirus) in preclinical cancer models* Cancer Inst. (1996) 88(10):144 AE TISHLER et al. "Microtubule-active drugs Taxol, V	Cite No.1	Cite No.¹ AA WO 95/10514 A1 04-20-1995 Schering Corp. AB WO 95/28948 A1 11-02-1995 Univ. Texas AC WO 97/23478 A1 07-03-1997 Schering Corp. NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate) (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issu publisher, city and/or country where published. AD HARRIS et al., "Structure and function of the p53 tumor suppressor gene: Clues for rational cance strategies" J. Natl. Cancer Inst. (1996) 88(20):1442-1455. AE NIELSEN et al., "Combination therapy with the Famesyl protein transferase inhibitor SCH66338 at Adenovirus) in preclinical cancer models" Cancer Research (1999) 59:5896-5901.	Cite No.¹ Country Code³ Number⁴ Kind Code³ (# Innown) AA WO 95/10514 A1 04-20-1995 Schering Corp. AB WO 95/28948 A1 11-02-1995 Univ. Texas AC WO 97/23478 A1 07-03-1997 Schering Corp. NON PATENT LITERATURE DOCUMENTS Cite No.¹ Cite No.¹ Cite No.¹ Cite No.¹ ABRIS et al., "Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies" J. Natl. Cancer Inst. (1998) 88(20):1442-1455. AE NIELSEN et al., "Combination therapy with the Famesyl protein transferase inhibitor SCH66338 and SCH58500 (p53 Adenovirus) in preclinical cancer models" Cancer Research (1999) 59:5896-5901. Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document Passages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear AD Univ. Texas Schering Corp. Publication Date MM-DD-YYYY Name of Patentee or Applicant of Cited Document Passages or Relevant Figures Appear Name of Patentee or Applicant of Cited Document Passages or Relevant Figures Appear Passages or Relevant Passages or Releva

60235769 v1

		·		
Examiner Signature	Joan Idr	Date Considered	4126105	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.